EDAP TMS S.A. Earnings Calls

Q4 2024 (Upcoming)
Release date Mar 27, 2025
EPS estimate -$0.110
EPS actual -
Revenue estimate 20.825M
Revenue actual -
Expected change +/- 9.72%
Q3 2024 Missed
-$0.190 (-18.75%)
Release date Nov 07, 2024
EPS estimate -$0.160
EPS actual -$0.190
EPS Surprise -18.75%
Revenue estimate 20.825M
Revenue actual 13.099M
Revenue Surprise -37.10%
Q2 2024 Missed
-$0.180 (-28.57%)
Release date Aug 28, 2024
EPS estimate -$0.140
EPS actual -$0.180
EPS Surprise -28.57%
Revenue estimate 17.52M
Revenue actual 15.791M
Revenue Surprise -9.87%
Q1 2024 Missed
-$0.130 (-30.00%)
Release date May 16, 2024
EPS estimate -$0.100
EPS actual -$0.130
EPS Surprise -30.00%
Revenue estimate 17.15M
Revenue actual 14.996M
Revenue Surprise -12.56%

Last 4 Quarters for EDAP TMS S.A.

Below you can see how EDAP performed 4 days prior and 4 days after releasing the earnings report. Also, you can see the pre-estimates and the actual earnings. This information can give you a slight idea of what you might expect for the next quarter's release.

Q1 2024 Missed
Release date May 16, 2024
Fiscal end date Mar 31, 2024
Price on release $6.89
EPS estimate -$0.100
EPS actual -$0.130
EPS surprise -30.00%
Date Price
May 10, 2024 $7.10
May 13, 2024 $7.10
May 14, 2024 $6.89
May 15, 2024 $6.88
May 16, 2024 $6.89
May 17, 2024 $6.71
May 20, 2024 $6.23
May 21, 2024 $6.01
May 22, 2024 $6.02
4 days before -2.96%
4 days after -12.63%
On release day -2.61%
Change in period -15.21%
Q2 2024 Missed
Release date Aug 28, 2024
Fiscal end date Jun 30, 2024
Price on release $2.99
EPS estimate -$0.140
EPS actual -$0.180
EPS surprise -28.57%
Date Price
Aug 22, 2024 $4.18
Aug 23, 2024 $4.05
Aug 26, 2024 $3.12
Aug 27, 2024 $2.87
Aug 28, 2024 $2.99
Aug 29, 2024 $3.26
Aug 30, 2024 $3.62
Sep 03, 2024 $3.49
Sep 04, 2024 $3.21
4 days before -28.47%
4 days after 7.36%
On release day 9.03%
Change in period -23.21%
Q3 2024 Missed
Release date Nov 07, 2024
Fiscal end date Sep 30, 2024
Price on release $2.73
EPS estimate -$0.160
EPS actual -$0.190
EPS surprise -18.75%
Date Price
Nov 01, 2024 $2.86
Nov 04, 2024 $2.69
Nov 05, 2024 $2.76
Nov 06, 2024 $2.84
Nov 07, 2024 $2.73
Nov 08, 2024 $2.57
Nov 11, 2024 $2.54
Nov 12, 2024 $2.64
Nov 13, 2024 $2.63
4 days before -4.55%
4 days after -3.66%
On release day -5.86%
Change in period -8.04%
Q4 2024 (Upcoming)
Release date Mar 27, 2025
Fiscal end date Dec 30, 2024
Price on release -
EPS estimate -$0.110
EPS actual -
Date Price
Mar 11, 2025 $2.39
Mar 12, 2025 $2.34
Mar 13, 2025 $2.33
Mar 14, 2025 $2.25
Mar 17, 2025 $2.29

EDAP TMS S.A. Earnings Call Transcript Summary of Q3 2024

  • HIFU Business Growth: Revenue from the Focal One HIFU business increased by 48.2%, with three systems placed during the quarter. Notable placements were made at Virginia Commonwealth University, Italy, and Spain.
  • Procedure Growth: U.S. Focal One HIFU procedures grew by 34% year-over-year, indicating strong adoption among urologists.
  • Reimbursement Update: Favorable reimbursement rates for HIFU procedures with CMS finalizing a Medicare hospital payment rate of $9,247 for 2025 (+5.4% from 2024).
  • Strategic Developments:
  • AI Collaboration: EDAP announced a collaboration with Avenda Health to launch AI-assisted Focal One robotic HIFU procedures, aiming to provide more personalized patient treatments.
  • Urology Meetings: The company had a significant presence at major urology-focused scientific meetings, leading to increased interest and engagement with Focal One technology.
  • Clinical Development:
  • BPH and Endometriosis Programs: The company is progressing with its clinical studies for benign prostatic hyperplasia (BPH) and endometriosis. Results from the BPH study expected later next year, and a U.S. clinical trial is anticipated to commence based on findings from the ongoing studies. For endometriosis, long-term patient follow-ups are underway, with positive indications for safety and efficacy.
  • Management Changes:
  • Leadership Update: Dr. Lance Willsey has been appointed Interim Board Chair following the departure of Marc Oczachowski.
  • Investor Insights:
  • Pipeline Growth: Expectations for a stronger second half of the year with increased hospital placements and pipeline expansion.
  • Market Positioning: EDAP aims to establish Focal One as a leading treatment modality for prostate cancer, positioned between active surveillance and radical therapy.
  • Overall Perspective: EDAP TMS demonstrated strong growth in revenue and procedure volume, along with strategic collaborations and ongoing clinical studies, positioning itself favorably in the urology market. Investors are encouraged by the company's expanding footprint, technological advancements, and positive reimbursement landscape, while watching for future clinical data releases and the impact of new hospital partnerships.
  • EDAP TMS S.A. Earnings History

    Earnings Calendar

    FAQ

    When is the earnings report for EDAP?
    EDAP TMS S.A. (EDAP) has scheduled its earnings report for Mar 27, 2025 before the markets open.

    What is the EDAP price-to-earnings (P/E) ratio?
    EDAP P/E ratio as of Mar 17, 2025 (TTM) is -3.55.

    What is the EDAP EPS forecast?
    The forecasted EPS (Earnings Per Share) for EDAP TMS S.A. (EDAP) for the first fiscal quarter 2024 is -$0.110.

    What are EDAP TMS S.A.'s retained earnings?
    On its balance sheet, EDAP TMS S.A. reported retained earnings of $13.10 million for the latest quarter ending Sep 30, 2024.

    What Is an Earnings Report?
    An earnings report is usually issued quarterly (Q1, Q2, Q3 & Q4) by public companies to report their performance. Earnings reports typically include net income, earnings per share, earnings from continuing operations, and net sales. Looking at the earnings report investors can start gauge the financial health of the company and make even better decisions whether to buy, sell, or stay in the company. Fundamental analysts and value investors will typically hunt for stocks that continue to show good financial ratios and use a decline as an exit point. One of the most anticipated numbers for analysis is earnings per share because it indicates how much the company earned for its shareholders. The report will also indicate a possible dividend.

    Earnings Report Content
    Earnings reports generally provide an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. These figures are typically measured against previous quarters/years. Furthermore, the earnings report usually includes a summary and analysis from the CEO or company spokesman, alongside a more general view of the financials and future forecast.

    What To Know About Earnings Reports?
    Announcement of earnings for a stock, particularly for well followed large-capitalization stocks, can move the market. Stock prices can fluctuate wildly on days when the quarterly earnings report is released. Despite good reports, stocks may very well fall if the investors were expecting more or they believe the next quarter will not be as good. Investors always try to be ahead of the market and future earnings/losses are often discounted into the current price of the stock. It is natural for stocks to start to move in either direction a few days before the release of an earnings report.
    Click to get the best stock tips daily for free!
    ABOUT EDAP TMS S.A.
    EDAP TMS S.A.
    EDAP TMS S.A., together with its subsidiaries, develops, produces, markets, distributes, and maintains a portfolio of minimally invasive medical devices for the treatment of urological diseases in Asia, France, the United States, and internationally. It operates in three segments: High Intensity Focused Ultrasound (HIFU), Extracorporeal ShockWave Lithotripsy (ESWL), and Distribution Services (DIST). The HIFU segment develops, manufactures, and ma...
    GOLDEN STAR
    Ticker Change Signal Date
    DESP
    $19.20
    0.260% Mar 13
    AMED
    $92.59
    0.0540% Mar 13
    O
    ODD
    $44.71
    4.18% Mar 13
    ALE
    $65.32
    0.138% Mar 12
    HESM
    $40.63
    6.25% Mar 11

    Top Fintech Company

    StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

    Full report by FINDEXABLE